Endpoints 11 winner 2025: Stylus Medicine wants to bring CAR-T to the massesnews2025-09-19T14:00:11+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Averna Therapeutics wants to harness jumping genesnews2025-09-19T14:00:07+00:00September 19th, 2025|Endpoints News|
Shape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2Bnews2025-09-18T13:45:49+00:00September 18th, 2025|Endpoints News|
ArsenalBio, a well-funded cell therapy startup, halves workforce to focus resourcesnews2025-09-18T02:55:31+00:00September 18th, 2025|Endpoints News|
AGC Bio to sell two sites in Colorado, will lay off 278 workers in the processnews2025-09-17T14:41:51+00:00September 17th, 2025|Endpoints News|
Affini-T CEO appears to have left startup, raising questions about company’s shutdownnews2025-09-17T12:18:28+00:00September 17th, 2025|Endpoints News|
Patient dies in Capsida study for rare brain disordernews2025-09-11T07:20:19+00:00September 11th, 2025|Endpoints News|
Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 studynews2025-09-10T13:39:50+00:00September 10th, 2025|Endpoints News|
New FDA approval pathway for n-of-1 therapies coming soon, Prasad saysnews2025-09-08T18:57:01+00:00September 8th, 2025|Endpoints News|
China biotech Epigenic raises $60M to test CRISPR epigenetic therapiesnews2025-09-08T02:00:04+00:00September 8th, 2025|Endpoints News|
